Benedicte Manoury

Benedicte Manoury


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1998 in Nature
Verified
Journal Article
Closed access
PDF file
BMBenedicte Manoury
Benedicte Manoury
EHEric Hewitt
Eric Hewitt
NMNick Morrice
Nick Morrice
PDPam M. Dando
Pam M. Dando
ABAlan J. Barrett
Alan J. Barrett
CWColin Watts
Colin Watts

1 November 2009 in Immunity
Verified
Journal Article
Closed access
FSFernando E. Sepulveda
Fernando E. Sepulveda
SMSophia Maschalidi
Sophia Maschalidi
RCRenaud Colisson
Renaud Colisson
LHLea Heslop
Lea Heslop
CGCristina Ghirelli
Cristina Ghirelli
BMBenedicte Manoury
Benedicte Manoury

5 September 2003 in Science
Verified
Journal Article
Closed access
PDF file
YYYili Yin
Yili Yin
BMBenedicte Manoury
Benedicte Manoury
RFRobin Fåhraeus
Robin Fåhraeus
The glycine-alanine repeat domain (GAr) of Epstein-Barr virus–encoded nuclear antigen 1 (EBNA1) prevents major histocompatibility complex (MHC) class I–restricted presentation of EBNA1 epitopes to cytotoxic T cells. This effect has previously been attributed to the ability of GAr to inhibit its own proteasomal degradation. Here we show, both in vitro and in vivo, that GAr also inhibits messenger RNA translation of EBNA1 in cis and that this effect can be distinguished from its effect on proteasomal degradation. Hence, inhibition of messenger RNA translation, but not protein degradation, is essential to prevent antigen presentation on MHC class I molecules. Thus, by minimizing translation of the EBNA1 transcript, cells expressing EBNA1 avoid cytotoxic T cell recognition. At the same time, blocking degradation maintains the EBNA1 expression level.

1 March 2001 in Current Biology
Verified
Journal Article
Closed access
BMBenedicte Manoury
Benedicte Manoury
WGWilliam F. Gregory
William F. Gregory
RMRick M. Maizels
Rick M. Maizels
CWColin Watts
Colin Watts

14 January 2002 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
BMBenedicte Manoury
Benedicte Manoury
DMDaniela Mazzeo
Daniela Mazzeo
LFLars Fugger
Lars Fugger
NVNick Viner
Nick Viner
MPMary Ponsford
Mary Ponsford
CWColin Watts
Colin Watts

27 June 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
SASebastien Apcher
Sebastien Apcher
CDChrysoula Daskalogianni
Chrysoula Daskalogianni
FLFabrice Lejeune
Fabrice Lejeune
BMBenedicte Manoury
Benedicte Manoury
GIGabriela Imhoos
Gabriela Imhoos
Robin FahraeusRobin Fahraeus
Robin Fahraeus
The MHC class I antigen presentation pathway allows the immune system to distinguish between self and nonself. Despite extensive research on the processing of antigenic peptides, little is known about their origin. Here, we show that mRNAs carrying premature stop codons that prevent the production of full-length proteins via the nonsense-mediated decay pathway still produce a majority of peptide substrates for the MHC class I pathway by a noncanonical mRNA translation process. Blocking the interaction of the translation initiation factor eIF4E with the cap structure suppresses the synthesis of full-length proteins but has only a limited effect on the production of antigenic peptides. These results reveal an essential cell biological function for a class of translation products derived during the pioneer round of mRNA translation and will have important implications for understanding how the immune system detects cells harboring pathogens and generates tolerance.